Health & Fitness
Health and Fitness
Health and Fitness
Tue, June 15, 2010 ZymoGenetics to Webcast Presentation at the Piper Jaffray Europe Conference
SEATTLE--([ BUSINESS WIRE ])--ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that James A. Johnson, Executive Vice President and Chief Financial Officerof ZymoGenetics, will present at the Piper Jaffray Europe Conference in London on Wednesday, June 23, 2010 at 11:00 a.m. GMT.
A live webcast of the presentation can be accessed by going to: [ www.zymogenetics.com ]. The webcast will be archived for 30 days.
About ZymoGenetics
ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases. The company has developed and is marketing RECOTHROM® Thrombin, topical (Recombinant) in the United States. ZymoGenetics has two product candidates in Phase 2 clinical development: PEG-Interferon lambda, being studied in collaboration with Bristol Myers Squibb for treatment of hepatitis C virus (HCV) infection, and IL-21, being tested by ZymoGenetics as a potential treatment for metastatic melanoma. In addition, ZymoGenetics has an anti-IL-31 monoclonal antibody in preclinical development, which it expects to test initially as a treatment for atopic dermatitis. Several of the product candidates previously identified through ZymoGeneticsa™ discovery research efforts have been licensed to and are being developed by third parties, including Merck Serono and Novo Nordisk. ZymoGenetics is eligible to receive milestone payments and royalties related to these assets. For further information, visit [ www.zymogenetics.com ].
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics.These statements are not guarantees of future actions and involve uncertainties that are difficult to predict. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.
